Patients have always had the numbers. What they have never had is a shared political identity. After 30 years in patient advocacy, Matthew Zachary argues that the next chapter may be transforming shared healthcare experiences into civic and political power.

A heart transplant survivor lost affordable access to the drug keeping her alive. It took two viral stories, a grieving donor mother, a nonprofit, and Mark Cuban to fix it. The happy ending is the problem: nobody should need an audience, influence, or a billionaire to get healthcare.

Doctors know how to treat their patients. Increasingly, they’re being blocked from doing it. After decades in patient advocacy, I’m realizing that patients and physicians may be fighting different sides of the same healthcare battle.

Sydney Towle didn’t fail to look sick enough. We failed to understand what living with cancer can actually look like. Her story exposes a culture that demands patients perform suffering before offering compassion, and what that says about all of us.

More than 80% of appealed Medicare Advantage prior authorization denials are overturned, yet fewer than 0.2% of ACA Marketplace denials are ever appealed. The problem is not only denial. It is a system that profits when patients run out of time, energy, and hope.

UnitedHealth helped shape research behind the No Surprises Act expecting greater leverage over providers. Then neutral arbiters started ruling against insurers. Now it wants the rules changed. Wendell Potter’s reporting reveals how healthcare power works behind the scenes.

Concierge medicine used to be for the rich. Now ordinary patients are paying out of pocket for advocates, navigators, and direct access just to get the care their insurance was supposed to provide in the first place. Welcome to the second bill nobody asked for.

A retired firefighter’s denied cancer treatment reveals a larger truth about American healthcare. Administrative friction has become an economic strategy that shifts costs onto patients and physicians while delaying care in ways the system rarely measures but patients always feel.

Americans now need books to survive healthcare. That’s not evidence of empowerment. It’s evidence of failure. As affordability collapses and complexity grows, patients are being forced to become advocates, navigators, and administrators just to access care they already pay for.

ASCO 2026 delivered extraordinary advances in cancer research, including a standing ovation for a pancreatic cancer breakthrough. Yet the dominant conversation centered on something else: the widening gap between scientific innovation and patients’ ability to access it.

Brain cancer at 21 forced Matthew Zachary into the American healthcare system decades before he understood its economics, incentives, and failures. At 52, he reflects on how surviving long enough to see the whole machine clearly led to writing We the Patients.

Cancer patients increasingly absorb the financial risk of surviving disease in America. A brain cancer survivor examines how healthcare incentives, insurance design, and policy decisions shifted instability onto patients and families while institutions protect margins.

Mark Cuban attacks healthcare through pricing transparency and market discipline. I would attack it through patient infrastructure, legal protection, accountability, and civic power. Together, those strategies could finally begin realigning the incentives driving American healthcare.

Millions of eczema patients increasingly distrust the treatments medicine tells them to rely on. Matthew Zachary examines topical steroid withdrawal, chronic inflammation, patient distrust, and the healthcare incentives driving one of medicine’s fastest growing credibility crises

Hospitals blame insurers. Insurers blame hospitals. Patients finance the entire system through premiums, deductibles, debt, and confusion. Matthew Zachary examines the incentive structures, financial flows, and institutional dependencies that keep American healthcare expensive, opaque, and exhausting.

For 20 years, chemical reform promised protection. The system still allows widespread exposure while shifting risk to patients. This analysis explains how incentives, not science, determine what ends up in the products people use every day.

I paid $13.18 for a 90 day prescription through Cost Plus. Walgreens charged $30 with insurance. Same drug. Same supply. This is what PBMs do to pricing and why transparency exposes the middlemen.

Prior authorization persists because it works for the system that created it. This essay explains how cost control, risk management, and delay shape patient outcomes, why reform keeps falling short, and what must change to align financial incentives with timely care.

Only 0.2% of patients appeal insurance denials, yet 80% succeed. This article examines how even small increases in appeals could shift insurer behavior, raise costs, influence Wall Street expectations, and reshape the economics of American healthcare.

American healthcare delays care and denies treatment by design. Insurance rules, prior authorization, and administrative barriers control access to care, often slowing or blocking what doctors recommend and patients need.